Press Releases

January 8, 2021
Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule
MALVERN, Pa., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq
Additional Formats
Displaying 31 - 33 of 33